The Body Covers: The 9th Conference on Retroviruses and Opportunistic Infections
Antiretroviral Chemotherapy: New Agents (Oral Abstract Session 4)
February 25, 2002
The comparator regimen was chosen from the previously-conducted ERA study, and consisted of AZT/3TC/abacavir/indinavir/nevirapine; results were published in the journal AIDS in 1998. In this study, early viral load measurements were done at days 0, 1, 3, 4, and 7, versus daily in the TMC125 study. Compared with the TMC125 study group, at baseline those in the ERA study were older and had slightly higher baseline viral loads and lower CD4 cell counts.
Based on the seven-day measurements, the following results were obtained:
Although cross-study comparisons should be made cautiously, these data underscore the robust antiviral activity of TMC125 in drug-naive patients, achieving at seven days results comparable to a five-drug regimen. As noted in Abstract 4, TMC125 also has activity (albeit somewhat lower in magnitude) in most patients who have experienced virologic failure to NNRTIs. The excitement about TMC125's ongoing development must be tempered somewhat by the drug's currently unpalatable formulation, which requires ingestion of 18 tablets twice daily! On an encouraging note, Tibotec is actively pursuing a more user-friendly formulation, one that will significantly reduce this pill burden.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.